Matching-adjusted indirect comparisons of oral rimegepant versus placebo, erenumab, and galcanezumab examining monthly migraine days and health-related quality of life in the treatment of migraine.
第一作者:
Evan,Popoff
第一单位:
Broadstreet Health Economics & Outcomes Research, Vancouver, BC, Canada.
作者:
主题词
投药, 口服(Administration, Oral);成年人(Adult);降钙素基因相关肽(Calcitonin Gene-Related Peptide);女(雌)性(Female);人类(Humans);男(雄)性(Male);中年人(Middle Aged);偏头痛(Migraine Disorders);哌啶类(Piperidines);安慰剂(Placebos);吡啶类(Pyridines);生活质量(Quality of Life);治疗结果(Treatment Outcome)
DOI
10.1111/head.14128
PMID
34021585
发布时间
2021-12-14
- 浏览1

Headache
906-915页
相似文献
- 中文期刊
- 外文期刊
- 学位论文
- 会议论文